U.S. markets closed

Eliem Therapeutics, Inc. (ELYM)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
2.6300+0.0100 (+0.38%)
At close: 03:50PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close2.6200
Bid2.5700 x 800
Ask2.6300 x 1100
Day's Range2.6000 - 2.7300
52 Week Range2.2100 - 4.7500
Avg. Volume34,298
Market Cap71.245M
Beta (5Y Monthly)0.47
PE Ratio (TTM)N/A
EPS (TTM)-1.7000
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ELYM

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Eliem Therapeutics, Inc
    Daily – Vickers Top Buyers & Sellers for 08/18/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    2 years agoArgus Research
View more
  • Simply Wall St.

    Eliem Therapeutics (NASDAQ:ELYM) Is In A Good Position To Deliver On Growth Plans

    Just because a business does not make any money, does not mean that the stock will go down. For example, although...

  • Zacks

    Eliem (ELYM) to Explore Strategic Options, Stock Rises 6%

    Eliem (ELYM) announces its decision to halt its Kv7 development program in its quest to explore strategic alternatives. The stock of the company rises 6% in response on Thursday.

  • GlobeNewswire

    Eliem Therapeutics Announces Plans to Explore Strategic Alternatives

    SEATTLE and CAMBRIDGE, United Kingdom, July 20, 2023 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM) today announced that it has completed a review of its business, including the status of its programs, resources, and capabilities, and has made the determination to halt further development of its Kv7 program and to conduct a comprehensive exploration of strategic alternatives focused on maximizing shareholder value. Eliem has engaged Leerink Partners to act as a strategic advisor in